Delivery Order SPE2DB20D1100-SPE2DB24FA6K9
Award Date
3/8/24
Potential Completion Date
3/29/24
Potential Value
$116K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, issued by the Defense Logistics Agency (DLA), was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,038.58, is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of March 24, 2025 and is a firm fixed-price contract. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award, valued at $48,077.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 mg/10 ml vials, a specialty medication, to support federal healthcare programs. The contract has an ultimate completion date of March 12, 2025, and it is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside....
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on January 28, 2025. The contract was not set aside for any specific business category. In addition to this delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of February 28, 2025 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $60,096.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a fixed price and a completion date of February 18, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, with ID SPE2DX15D1053|SPE2DX25F6NCD, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Ocrevus 300 mg/10 ml vials. The contract is a firm fixed-price delivery order with a ceiling value of $120,192.80 and a period of performance through May 27, 2025. The contract is not designated as a set-aside. As a prime contractor, AmerisourceBergen Drug Corp holds a substantial Indefinite...
This federal contract award, valued at $120,192.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order, provides the DLA with OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS (ocrelizumab) 300 mg/10 ml vials. The $46,236.16 firm fixed-price delivery order has an ultimate completion date of October 18, 2024. The award is not associated with a set-aside program. This contract is likely part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,038.58, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of April 23, 2025, and is a firm fixed-price delivery order. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite...
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to provide Ocrevus 300 mg/10 ml vials. The fixed-price contract, valued at $69,354.24, has a completion date of June 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for...